⚠ coups-regime · severity 2/5
Biotech takeover target Abivax sinks over 30% after bowel disease drug trial update
—·27d
Shares of French biotech Abivax tumbled 32% after it reported fresh data on its lead asset.
ChannelsstocksCountriesusaCategoriesmergers-acquisitions
Open original source ↗Published
6/2/2026, 8:24:13 AM
Fetched
6/2/2026, 9:07:35 AM
Confidence
60 / 100
Relevance
49 / 100
Trust
—
Language
en